{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:31:56Z","timestamp":1791318716125,"version":"4.3.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Laboratory and Clinical Medicine"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1067\/mlc.2001.119285","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T18:14:26Z","timestamp":1030212866000},"page":"367-377","source":"Crossref","is-referenced-by-count":48,"title":["Cellular pathophysiology and therapy of pulmonary hypertension"],"prefix":"10.1067","volume":"138","author":[{"given":"Horst","family":"Olschewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Walmrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Schermuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Grimminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mlc.2001.119285_bib1","series-title":"Primary pulmonary hypertension: Executive summary from the world symposium\u2014Primary pulmonary hypertension","year":"1998"},{"key":"10.1067\/mlc.2001.119285_bib2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/01.CIR.102.10.1145","article-title":"Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene","volume":"102","author":"Gr\u00fcnig","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1067\/mlc.2001.119285_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/geno.2000.6291","article-title":"A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension","volume":"68","author":"Machado","year":"2000","journal-title":"Genomics"},{"key":"10.1067\/mlc.2001.119285_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jmg.37.10.741","article-title":"Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family","volume":"37","author":"Thomson","year":"2000","journal-title":"J Med Genet"},{"key":"10.1067\/mlc.2001.119285_bib6","first-page":"139","article-title":"Mortality in systemic sclerosis (sleroderma)","volume":"82","author":"Lee","year":"1992","journal-title":"QJM"},{"key":"10.1067\/mlc.2001.119285_bib7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1164\/ajrccm.162.4.9912131","article-title":"Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study","volume":"162","author":"Yi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib8","doi-asserted-by":"crossref","first-page":"C970","DOI":"10.1152\/ajpcell.2001.280.4.C970","article-title":"Activation of K+ channels induces apoptosis in vascular smooth muscle cells","volume":"280","author":"Krick","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1067\/mlc.2001.119285_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.physiol.59.1.89","article-title":"Cellular and molecular mechanisms of pulmonary vascular remodeling","volume":"59","author":"Stenmark","year":"1997","journal-title":"Annu Rev Physiol"},{"key":"10.1067\/mlc.2001.119285_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1165\/ajrcmb.22.1.3536","article-title":"Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts: potential contribution of specific protein kinase C isozymes","volume":"22","author":"Das","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1067\/mlc.2001.119285_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/ajrcmb.22.1.f172","article-title":"Adventitial fibroblasts: defining a role in vessel wall remodeling","volume":"22","author":"Strauss","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1067\/mlc.2001.119285_bib12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.CIR.98.14.1400","article-title":"Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension","volume":"14","author":"Yuan","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0140-6736(05)60264-4","article-title":"Action of fenfluramine on voltage-gated K+ channels in human pulmonary artery smooth-muscle cells","volume":"352","author":"Wang","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mlc.2001.119285_bib14","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1172\/JCI119774","article-title":"Hypoxia inhibits gene expression of voltage-gated K+ channel \u03b1 subunits in pulmonary artery smooth muscle cells","volume":"100","author":"Wang","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1067\/mlc.2001.119285_bib15","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","article-title":"Primary pulmonary hypertension. A vascular biology and translational research \u201cwork in progress.\u201d","volume":"102","author":"Archer","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/01.RES.81.6.940","article-title":"Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities","volume":"81","author":"Frid","year":"1997","journal-title":"Circ Res"},{"key":"10.1067\/mlc.2001.119285_bib17","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1067\/mlc.2001.119285_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1164\/ajrccm.159.2.9805075","article-title":"Role of hemodynamics in pulmonary vascular remodeling\u2014implications for primary pulmonary hypertension","volume":"159","author":"Botney","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1172\/JCI1910","article-title":"Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension","volume":"101","author":"Lee","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1067\/mlc.2001.119285_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1183\/09031936.99.14612469","article-title":"Severe pulmonary hypertensive diseases: a perspective","volume":"14","author":"Voelkel","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1067\/mlc.2001.119285_bib21","doi-asserted-by":"crossref","first-page":"213S","DOI":"10.1378\/chest.114.3_Supplement.213S","article-title":"Elastase and the pathobiology of unexplained pulmonary hypertension","volume":"114","author":"Rabinovitch","year":"1998","journal-title":"Chest"},{"key":"10.1067\/mlc.2001.119285_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/76282","article-title":"Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor","volume":"6","author":"Cowan","year":"2000","journal-title":"Nat Med"},{"key":"10.1067\/mlc.2001.119285_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs front patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1172\/JCI5911","article-title":"Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension","volume":"103","author":"Geraci-MW","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1067\/mlc.2001.119285_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-3476(05)81552-5","article-title":"Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension","volume":"123","author":"Rosenberg","year":"1993","journal-title":"J Pediatr"},{"key":"10.1067\/mlc.2001.119285_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1164\/ajrccm\/148.2.519","article-title":"Circulating immunoreactive endothelin-1 in children with pulmonary hypertension","volume":"148","author":"Allen","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1067\/mlc.2001.119285_bib28","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1067\/mlc.2001.119285_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib31","first-page":"H1921","article-title":"Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms","volume":"267","author":"McQuillan","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1067\/mlc.2001.119285_bib32","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1378\/chest.109.6.1545","article-title":"Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests","volume":"109","author":"Channick","year":"1996","journal-title":"Chest"},{"key":"10.1067\/mlc.2001.119285_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0735-1097(99)00494-5","article-title":"A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension","volume":"35","author":"Hoeper","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mlc.2001.119285_bib34","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1164\/ajrccm.158.5.9802114","article-title":"Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury","volume":"158","author":"Jacobs","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib35","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00003246-199808000-00026","article-title":"Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension","volume":"26","author":"Brilli","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib36","first-page":"985","article-title":"Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation","volume":"282","author":"Sch\u00fctte","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1067\/mlc.2001.119285_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI118795","article-title":"Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats","volume":"98","author":"Janssens","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1067\/mlc.2001.119285_bib38","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1161\/01.CIR.102.23.2880","article-title":"Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats","volume":"102","author":"Budts","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herv\u00e9","year":"1995","journal-title":"Am J Med"},{"key":"10.1067\/mlc.2001.119285_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1067\/mlc.2001.119285_bib41","doi-asserted-by":"crossref","first-page":"200S","DOI":"10.1378\/chest.114.3_Supplement.200S","article-title":"A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension","volume":"114","author":"Weir","year":"1998","journal-title":"Chest"},{"key":"10.1067\/mlc.2001.119285_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1034\/j.1399-3003.2000.15b28.x","article-title":"Thrombotic risk factors in pulmonary hypertension","volume":"15","author":"Wolf","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1067\/mlc.2001.119285_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-2143(99)90094-X","article-title":"Prothrombotic mechanisms in primary pulmonary hypertension","volume":"134","author":"Farber","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1067\/mlc.2001.119285_bib44","first-page":"650","article-title":"A putative role for fibrin(ogen) cleavage products and thrombin as mediators of vascular remodelling","volume":"3","author":"Gray","year":"1993","journal-title":"Eur Respir Rev"},{"key":"10.1067\/mlc.2001.119285_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1055\/s-0038-1653857","article-title":"Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension","volume":"73","author":"Boyer-Neumann","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1067\/mlc.2001.119285_bib46","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib48","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1161\/01.CIR.96.9.2782","article-title":"Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension","volume":"96","author":"Friedman","year":"1997","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib49","first-page":"747","article-title":"Impairment of hypoxic pulmonary artery remodeling by heparin in mice","volume":"128","author":"Hales","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1067\/mlc.2001.119285_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1164\/ajrccm\/148.1.241","article-title":"Effect of heparin on the development of hypoxic pulmonary hypertension in the guinea pig","volume":"148","author":"Spence","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1067\/mlc.2001.119285_bib51","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1183\/09031936.93.03080910","article-title":"Atrial natriuretic peptide in primary pulmonary hypertension","volume":"3","author":"Morice","year":"1990","journal-title":"Eur Respir J"},{"key":"10.1067\/mlc.2001.119285_bib52","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0735-1097(01)01490-5","article-title":"Regulation of atrial natriuretic peptide (ANP) in response to acute iloprost-induced pulmonary vasodilatation in severe pulmonary hypertension","volume":"38","author":"Wiedemann","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mlc.2001.119285_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1042\/CS19980070","article-title":"Increased plasma levels of adrenomedullin in patients with pulmonary hypertension","volume":"96","author":"Kakishita","year":"1999","journal-title":"Clin Sci (Colch)"},{"key":"10.1067\/mlc.2001.119285_bib55","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/01.CIR.101.5.498","article-title":"Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure","volume":"101","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib56","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1164\/ajrccm.162.4.2003124","article-title":"Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect Of prostacyclin therapy","volume":"162","author":"Eddahibi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib57","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0002-8703(93)90172-6","article-title":"Pulmonary hypertension is a contraindication to beta-blockade in patients with severe mitral stenosis","volume":"125","author":"Wisenbaugh","year":"1993","journal-title":"Am Heart J"},{"key":"10.1067\/mlc.2001.119285_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1067\/mlc.2001.119285_bib59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0735-1097(98)00361-1","article-title":"Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine","volume":"32","author":"Ricciardi","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mlc.2001.119285_bib60","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(99)03558-8","article-title":"Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial","volume":"354","author":"Kinsella","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mlc.2001.119285_bib61","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92033-X","article-title":"Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension","volume":"338","author":"Pepke-Zaba","year":"1991","journal-title":"Lancet"},{"key":"10.1067\/mlc.2001.119285_bib62","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.94.3.477","article-title":"Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hyperetension","volume":"94","author":"Williamson","year":"1996","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib63","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.101.17.2066","article-title":"Improvement in exercise capacity with nitric oxide inhalations in patients with precapillary pulmonary hypertension","volume":"101","author":"Hasuda","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1139\/y77-064","article-title":"Inhibition of hypoxic pulmonary vasoconstriction by dipyridamole is not platelet mediated","volume":"55","author":"Mlczoch","year":"1977","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1067\/mlc.2001.119285_bib65","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1164\/ajrccm.158.5.9710117","article-title":"Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension","volume":"158","author":"Ziegler","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1165\/ajrcmb\/3.4.301","article-title":"Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers","volume":"3","author":"Riva","year":"1990","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1067\/mlc.2001.119285_bib67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1164\/ajrccm.157.1.9704003","article-title":"5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension","volume":"157","author":"Wright","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 31","key":"10.1067\/mlc.2001.119285_bib68","first-page":"357s","article-title":"Anti-inflammatory effects of iloprost inhalation on PMN functions in patients with severe pulmonary hypertension [abstract]","volume":"16","author":"Rose","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1067\/mlc.2001.119285_bib69","first-page":"1326","article-title":"Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary hypertension","volume":"306","author":"Watkins","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib70","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib71","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1067\/mlc.2001.119285_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1067\/mlc.2001.119285_bib73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib75","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1378\/chest.116.4.914","article-title":"Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension","volume":"116","author":"Wax","year":"1999","journal-title":"Chest"},{"key":"10.1067\/mlc.2001.119285_bib76","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1378\/chest.114.5.1269","article-title":"A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension","volume":"114","author":"Robbins","year":"1998","journal-title":"Chest"},{"key":"10.1067\/mlc.2001.119285_bib77","first-page":"679","article-title":"The influence of continous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation","volume":"17","author":"Conte","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"10.1067\/mlc.2001.119285_bib78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1067\/mlc.2001.119285_bib79","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","article-title":"Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study","volume":"13","author":"Humbert","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1067\/mlc.2001.119285_bib80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.117.1.14","article-title":"Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematodes","volume":"117","author":"Robbins","year":"2000","journal-title":"Chest"},{"key":"10.1067\/mlc.2001.119285_bib81","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib82","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib83","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1067\/mlc.2001.119285_bib84","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/hrt.79.2.175","article-title":"Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost","volume":"79","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1067\/mlc.2001.119285_bib85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1067\/mlc.2001.119285_bib86","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","article-title":"Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension","volume":"34","author":"Nagaya","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mlc.2001.119285_bib87","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0140-6736(93)92004-D","article-title":"Aerosolized prostacyclin in adult respiratory distress syndrome","volume":"342","author":"Walmrath","year":"1993","journal-title":"Lancet"},{"key":"10.1067\/mlc.2001.119285_bib88","first-page":"724","article-title":"Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis","volume":"151","author":"Walmrath","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib89","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1164\/ajrccm.153.3.8630585","article-title":"Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome","volume":"153","author":"Walmrath","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib90","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1067\/mlc.2001.119285_bib91","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s001340050628","article-title":"Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost","volume":"24","author":"Olschewski","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1067\/mlc.2001.119285_bib92","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib93","first-page":"923","article-title":"Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension","volume":"129","author":"Stricker","year":"1999","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1067\/mlc.2001.119285_bib94","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/01.CIR.101.20.2388","article-title":"Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension","volume":"101","author":"Wensel","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib95","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial","volume":"132","author":"Olschewski","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1067\/mlc.2001.119285_bib96","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1067\/mlc.2001.119285_bib97","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1164\/ajrccm.160.5.9901102","article-title":"Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension","volume":"160","author":"Schermuly","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mlc.2001.119285_bib98","first-page":"512","article-title":"Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange","volume":"292","author":"Schermuly","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1067\/mlc.2001.119285_bib99","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.CIR.101.8.923","article-title":"In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse","volume":"101","author":"Champion","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_NEWBIB1","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1161\/01.CIR.96.9.3180","article-title":"Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice","volume":"96","author":"Carmeliet","year":"1997","journal-title":"Circulation"},{"key":"10.1067\/mlc.2001.119285_bib101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/01.RES.88.1.103","article-title":"Soluble guanylate cyclase \u03b1(1) and \u03b2(1) gene transfer increases NO-responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects","volume":"88","author":"Sinnaeve","year":"2001","journal-title":"Circ Res"}],"container-title":["Journal of Laboratory and Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022214301719828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022214301719828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:07:53Z","timestamp":1680520073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022214301719828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S0022214301719828"],"URL":"https:\/\/doi.org\/10.1067\/mlc.2001.119285","relation":{},"ISSN":["0022-2143"],"issn-type":[{"value":"0022-2143","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}